Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1644
This examiner grants 66% of resolved cases
Phuong N Huynh is a high-volume examiner in Tech Center 1600, working in Art Unit 1641. With 1346 resolved cases, the examiner has one of the most extensive records available. This volume of 1346 cases provides a very high level of statistical confidence in the associated metrics. The data reveals an allowance rate of 65.8 percent, suggesting a favorable environment for applicants.
The median time to allowance is 1140 days. This 1140-day timeline represents the typical duration from filing to grant for this examiner. Practitioners should use this figure to manage timelines and expectations for applications in Art Unit 1641. The 65.8 percent allowance rate is a reliable baseline for any application assigned to this examiner in Tech Center 1600.
A standout metric for this examiner is the interview lift of 53.5 percent. This exceptionally high lift indicates that interviews are an extremely effective tool for advancing prosecution. A 53.5 percent increase in the likelihood of success following an interview is a very strong signal that practitioners should prioritize direct engagement. In Art Unit 1641, leveraging this 53.5 percent lift is likely the most effective way to improve upon the 65.8 percent base allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18499720 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | Non-Final OA | JANSSEN BIOTECH, INC. |
| 18555924 | MOLECULES WITH ENGINEERED ANTIBODY CONSTANT REGION VARIANTS | Non-Final OA | Janssen Biotech, Inc. |
| 17771227 | COMBINED INHIBITION OF PD-1, TGFB AND TIGIT FOR THE TREATMENT OF CANCER | Non-Final OA | MERCK PATENT GmbH |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | Final Rejection | Genentech, Inc. |
| 17628418 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | Final Rejection | The Regents of the University of Michigan |
| 18291283 | COMBINATIONS OF ANTIGEN BINDING MOLECULES | Non-Final OA | MORPHOSYS GMBH |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19329403 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | Final Rejection | Avidity Biosciences, Inc. |
| 18182093 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | Final Rejection | Bayer Aktiengesellschaft |
| 18570723 | TARGETED ADAM17 BLOCKER COMPOUNDS, ANTI-ADAM17 ANTIBODIES, METHODS OF MAKING, AND METHODS OF USING | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18185465 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | Final Rejection | SANOFI |
| 18256916 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | Non-Final OA | Purdue Research Foundation |
| 17961761 | NANOPARTICLE IMMUNOCONJUGATES | Final Rejection | The Curators of the University of Missouri |
| 18298743 | METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 13885646 | AGENTS AND METHODS FOR TREATING DISEASES THAT CORRELATE WITH BCMA EXPRESSION | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18430887 | METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN | Non-Final OA | Hoffmann-La Roche Inc. |
| 17507511 | ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE | Non-Final OA | Hoffmann-La Roche Inc. |
| 17507029 | THERAPEUTIC MULTISPECIFIC POLYPEPTIDES ACTIVATED BY POLYPEPTIDE CHAIN EXCHANGE | Non-Final OA | Hoffmann-La Roche Inc. |
| 17335702 | AFFINITY CHROMATOGRAPHY PURIFICATION WITH LOW CONDUCTIVITY WASH BUFFER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18248345 | RATIONAL SELECTION OF BUILDING BLOCKS FOR THE ASSEMBLY OF MULTISPECIFIC ANTIBODIES | Non-Final OA | AMGEN INC. |
| 18022685 | PHARMACEUTICAL FORMULATION | Non-Final OA | AMGEN INC. |
| 18551138 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | Non-Final OA | The University of Toledo |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | Final Rejection | The University of Toledo |
| 18274875 | NOVEL ESR1 DERIVED PEPTIDES AND USES THEREOF FOR NEOANTIGEN THERAPY | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | Non-Final OA | GENZYME CORPORATION |
| 17782980 | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18016308 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18584875 | B7H6 ANTIBODY AND USE THEREOF | Non-Final OA | HEFEI TG IMMUNOPHARMA CO., LTD. |
| 18012760 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | Final Rejection | SAPREME TECHNOLOGIES B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy